Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | FPR3 | P25089 | 1/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.30 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL509477 | 0.88 | CPB2 (0.37) | NR1H2 | |
| SCHEMBL27123113 | 0.77 | ITGB3 (0.37) | GPR119FAAH | |
| SCHEMBL28868811 | 0.76 | GPR119 (0.44) | GPR119FAAHKMT2APKMHSD11B1 | |
| SCHEMBL13650556 | 0.76 | ALDH1A1 (0.37) | GPR119FPR3FPR2KMT2AHTR2C | |
| SCHEMBL29726619 | 0.75 | TDP1 (0.46) | MEN1KMT2ATDP1 | |
| SCHEMBL6018866 | 0.75 | LSS (0.35) | GPR119NR1H2FPR3FPR2KDM5A | |
| SCHEMBL6018862 | 0.75 | LSS (0.35) | GPR119NR1H2FPR3FPR2KDM5A | |
| SCHEMBL4810634 | 0.74 | ALDH1A1 (0.38) | FPR3FPR2 | |
| SCHEMBL4818666 | 0.74 | ALDH1A1 (0.38) | FPR3FPR2 | |
| SCHEMBL4810639 | 0.74 | ALDH1A1 (0.38) | FPR3FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218713-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2022-07-14 | — | — | US | disclosed |
| US-20210113571-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2021-04-22 | — | — | US | disclosed |
| US-20200281933-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2020-09-10 | — | — | US | disclosed |
| US-20200030335-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2020-01-30 | — | — | US | disclosed |
| US-20190175603-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2019-06-13 | — | — | US | disclosed |
| US-20180303842-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2018-10-25 | — | — | US | disclosed |
| US-20170266194-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2017-09-21 | — | — | US | disclosed |
| EP-2380874-B1 | Pleuromutilin derivatives for the treatment of diseases mediated by microbes | NABRIVA THERAPEUTICS AG (AT) | 2016-12-28 | — | — | EP | disclosed |
| US-20140256731-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG (AT) | 2014-09-11 | — | — | US | disclosed |
| US-20130040954-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2013-02-14 | — | — | US | disclosed |
| US-8153689-B2 | Pleuromutilin derivatives for the treatment of diseases mediated by microbes | NABRIVA THERAPEUTICS AG (AT) | 2012-04-10 | — | — | US | disclosed |
| US-20120029072-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG | 2012-02-02 | — | — | US | disclosed |
| US-8071643-B2 | Pleuromutilin derivatives for the treatment of diseases mediated by microbes | NABRIVA THERAPEUTICS AG (AT) | 2011-12-06 | — | — | US | disclosed |
| EP-2380874-A2 | Pleuromutilin derivatives for the treatment of diseases mediated by microbes | Nabriva Therapeutics AG (AT) | 2011-10-26 | — | — | EP | disclosed |
| EP-2137143-B1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG (AT) | 2011-09-07 | — | — | EP | disclosed |
| US-20100035987-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG (AT) | 2010-02-11 | — | — | US | disclosed |
| EP-2137143-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | Nabriva Therapeutics AG (AT) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008113089-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG (AT) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200281933-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, PLEC, FABP6 | GPR119 335/4885NR1H2 873/4885FPR3 783/4885 |
| US-20140256731-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, PLEC, FABP6 | GPR119 401/4885NR1H2 719/4885FPR3 722/4885 |
| US-20220218713-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, PLEC, FABP6 | GPR119 383/4885NR1H2 909/4885FPR3 856/4885 |
| US-20130040954-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, PLEC, FABP6 | GPR119 401/4885NR1H2 719/4885FPR3 722/4885 |
| US-20190175603-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, PLEC, FABP6 | GPR119 335/4885NR1H2 873/4885FPR3 783/4885 |
| US-20170266194-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HRH4, HRH2, CHRM1 | GPR119 673/4885NR1H2 1541/4885FPR3 236/4885 |
| US-20100035987-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, FABP6, ALPI | GPR119 260/4885NR1H2 571/4885FPR3 1037/4885 |
| US-20200030335-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HRH4, HRH2, CHRM1 | GPR119 673/4885NR1H2 1541/4885FPR3 236/4885 |
| US-20210113571-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, PLEC, FABP6 | GPR119 383/4885NR1H2 909/4885FPR3 856/4885 |
| US-20180303842-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, PLEC, FABP6 | GPR119 335/4885NR1H2 873/4885FPR3 783/4885 |
| US-20120029072-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, FABP6, PLEC | GPR119 242/4885NR1H2 541/4885FPR3 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.